EUFOREA Comment on a Misleading Allergic Rhinitis Report [Letter].
作者信息
Scadding Glenis K, Smith Peter K, Hellings Peter W
机构信息
Department of Allergy & Rhinology, Royal National ENT Hospital; Division of Immunity and Infection, University College, London, UK.
Griffith University, School of Medicine, Southport, Queensland, 4215, Australia.
出版信息
Patient Prefer Adherence. 2023 Jul 29;17:1881-1883. doi: 10.2147/PPA.S431247. eCollection 2023.
Abstract
摘要
相似文献
1
EUFOREA Comment on a Misleading Allergic Rhinitis Report [Letter].
Patient Prefer Adherence. 2023 Jul 29;17:1881-1883. doi: 10.2147/PPA.S431247. eCollection 2023.
2
EUFOREA Comment on a Misleading Allergic Rhinitis Report [Response to Letter].
Patient Prefer Adherence. 2023 Aug 12;17:1963-1965. doi: 10.2147/PPA.S432460. eCollection 2023.
3
Allergic respiratory disease care in the COVID-19 era: A EUFOREA statement.
World Allergy Organ J. 2020 May 16;13(5):100124. doi: 10.1016/j.waojou.2020.100124. eCollection 2020 May.
4
Allergic Rhinitis in Childhood and the New EUFOREA Algorithm.
Front Allergy. 2021 Jul 14;2:706589. doi: 10.3389/falgy.2021.706589. eCollection 2021.
5
EUFOREA treatment algorithm for allergic rhinitis.
Rhinology. 2020 Dec 1;58(6):618-622. doi: 10.4193/Rhin20.376.
6
Rhinology future trends: 2017 EUFOREA debate on allergic rhinitis.
Rhinology. 2019 Feb 1;57(1):49-56. doi: 10.4193/Rhin18.076.
7
A EUFOREA comment on a lost comorbidity of asthma.
Allergy Asthma Clin Immunol. 2023 Jun 30;19(1):56. doi: 10.1186/s13223-023-00816-0.
8
YouTube as a source of (mis)information on allergic rhinitis.
Ann Allergy Asthma Immunol. 2022 Nov;129(5):612-617. doi: 10.1016/j.anai.2022.06.031. Epub 2022 Jul 14.
9
Allergic rhinitis - effective treatment according to the latest recommendations.
Otolaryngol Pol. 2022 Dec 15;76(6):45-59. doi: 10.5604/01.3001.0016.1488.
10
Stepwise approach towards adoption of allergen immunotherapy for allergic rhinitis and asthma patients in daily practice in Belgium: a BelSACI-Abeforcal-EUFOREA statement.
Clin Transl Allergy. 2019 Feb 4;9:1. doi: 10.1186/s13601-019-0243-1. eCollection 2019.
本文引用的文献
1
Patient Satisfaction and Sensory Attributes of Nasal Spray Treatments of Olopatadine Hydrochloride/Mometasone Furoate Monohydrate and Azelastine Hydrochloride/Fluticasone Propionate for Allergic Rhinitis in Australia - An Observational Real-World Clinical Study.
Patient Prefer Adherence. 2023 Jan 15;17:141-151. doi: 10.2147/PPA.S389875. eCollection 2023.
2
EUFOREA treatment algorithm for allergic rhinitis.
Rhinology. 2020 Dec 1;58(6):618-622. doi: 10.4193/Rhin20.376.
3
Real-life treatment of rhinitis in Australia: a historical cohort study of prescription and over-the-counter therapies for patients with and without additional respiratory disease.
Pragmat Obs Res. 2018 Aug 15;9:43-54. doi: 10.2147/POR.S153266. eCollection 2018.
4
MP29-02 reduces nasal hyperreactivity and nasal mediators in patients with house dust mite-allergic rhinitis.
Allergy. 2018 May;73(5):1084-1093. doi: 10.1111/all.13349. Epub 2018 Jan 17.
5
Cilia and Mucociliary Clearance.
Cold Spring Harb Perspect Biol. 2017 Apr 3;9(4):a028241. doi: 10.1101/cshperspect.a028241.
Zotero 插件